A Phase 2 interventional study of Ramucirumab DP and IMC-18F1 in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 37th largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2011, is one of 41 in phase 2, and was the 40th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 16 · Phase 4 4
First in 1998; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 138 across the 80 interventional studies. Of the 61 that completed or were terminated, 40 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Breast Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multicenter, randomized, Phase 2 trial in which participant with unresectable, locally advanced or metastatic breast cancer who have been previously treated with anthracycline and taxane therapy receive ramucirumab DP or Icrucumab (IMC-18F1) administered on an every-21-day cycle (in combination with oral capecitabine therapy; capecitabine is administered twice a day on Days 1-14 of each cycle). Approximately 150 participants will be randomized in a 1:1:1 ratio to either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine (Arm A and Arm B, respectively) or capecitabine monotherapy (Arm C). Randomization will be stratified by triple-negative receptor status (estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor-2 [HER2/neu]-negative) (yes/no) and receipt of prior antiangiogenic therapy.
Treatment with the study medication(s) will continue until disease progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision. Capecitabine dose reductions in the setting of significant myelosuppression, hand-and-foot syndrome, or diarrhea will be required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Does not have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
Biological: Ramucirumab DP · Drug: Capecitabine
Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
Biological: IMC-18F1 · Drug: Capecitabine
Crossover Study: \* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given. Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
Drug: Capecitabine
10 mg/kg I.V. Day 1 of every-21-day cycle
Also known as: IMC-1121B, LY3009806
12 mg/kg I.V. Days 1 and 8 of every-21-day cycle
Also known as: Icrucumab, LY3012212
1000 mg/m\^2 orally Twice a day for 14 days
Progression-Free Survival (PFS)
PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) and the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 97 weeks)
Overall Survival (OS)
Overall survival is defined as the time from the date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.
Time frame: From Date of Randomization until Death Due to Any Cause (Up To 160 weeks)
Percentage of Participants With Objective Response Rate (ORR)
The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm and the appearance of ≥1 new lesions was progression.
Time frame: From Date of Randomization until Disease Progression/Recurrence (Up to 97 weeks)
Duration of Response
Duration of response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that the criteria for progressive disease (PD) is met (taking as a reference for PD that smallest measurement recorded since the treatment started), or death, is objectively documented.CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.PD defined as ≥20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). Sum must also have demonstrated an absolute increase of ≥5 mm, or the appearance of 1 or more new lesions was considered progression.
Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up To 97 weeks)
Number of Participants With Adverse Events (AEs)
Adverse event (AE) will be regarded as treatment-emergent if onset date occurs any time on or after the administration of the first dose of study treatment up to 30 days after the last dose of study treatment (or up to any time if related to study treatment); or it occurs prior to first dose date and worsens while on therapy or up to 30 days after the last dose of study treatment (or up to any time if related to study treatment). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up To 160 Weeks
Number of Participants With Serious Adverse Events (SAEs)
SAE was defined as any untoward medical occurrence that at any dose: Resulted in death; Was life-threatening; Required inpatient hospitalization or caused prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Required intervention to prevent permanent impairment/damage; Was an important medical event (defined as a medical event that may not have been immediately life-threatening or resulted in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention to prevent one of the other serious outcomes listed in the definition above). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up To 160 Weeks
Maximum Concentration (Cmax) Ramucirumab Drug Product (DP) or Icrucumab
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Minimum Concentration (Cmin) Ramucirumab Drug Product (DP) or Icrucumab
Minimum Concentration (Cmin) Ramucirumab Drug Product (DP) or Icrucumab.
Time frame: Cycle 2,4,6,8,0,12,14,16,18,22: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Ramucirumab or Icrucumab
Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity of Ramucirumab and Icrucumab.
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Terminal Half-life (t½) of Ramucirumab or Icrucumab
Terminal half-life (t½) of Ramucirumab and Icrucumab.
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Clearance (Cl) of Ramucirumab or Icrucumab
Clearance (Cl) of Ramucirumab and Icrucumab.
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Volume of Distribution at Steady State (Vss) of Ramucirumab or Icrucumab
Volume of Distribution at Steady State (Vss) of Ramucirumab and Icrucumab.
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Number of Participants With Anti-Ramucirumab and Anti-Icrucumab Antibodies
Time frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion
Participants in Capecitabine arm were allowed to cross-over to ramucirumab or icrucumab in combination with capecitabine, after radiographic disease progression while on capecitabine.
| Milestone | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Started | 52 | 51 | 50 |
| Received at least one dose of study drug | 52 | 49 | 49 |
| Capecitabine crossover to ramucirumab | 0 | 0 | 29 |
| Capecitabine crossover to icrucumab | 0 | 0 | 1 |
| Completed | 51 | 45 | 42 |
| Not completed | 1 | 6 | 8 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 | 4 |
| Withdrew: Never treated: death | 0 | 0 | 1 |
| Withdrew: Never treated: withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Never treated: insurance denied xeloda | 0 | 1 | 0 |
PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) and the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.
| Weeks | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Progression-Free Survival (PFS) | 22.1 (12.1 to 36.1) | 7.3 (6.3 to 13.0) | 19.0 (12.1 to 24.3) |
Overall survival is defined as the time from the date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.
| Weeks | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Overall Survival (OS) | 67.4 (41.3 to 82.6) | 62.1 (41.0 to 84.0) | 71.6 (57.4 to 89.7) |
The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm and the appearance of ≥1 new lesions was progression.
| Percentage of Participants | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) | 28.8 (17.1 to 43.1) | 20.4 (10.2 to 34.3) | 34.7 (21.7 to 49.6) |
Duration of response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that the criteria for progressive disease (PD) is met (taking as a reference for PD that smallest measurement recorded since the treatment started), or death, is objectively documented.CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.PD defined as ≥20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). Sum must also have demonstrated an absolute increase of ≥5 mm, or the appearance of 1 or more new lesions was considered progression.
| weeks | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Duration of Response | 43.1 (12.0 to 49.0) | 20.1 (1.9 to 33.9) | 17.1 (6.4 to 30.7) |
Adverse event (AE) will be regarded as treatment-emergent if onset date occurs any time on or after the administration of the first dose of study treatment up to 30 days after the last dose of study treatment (or up to any time if related to study treatment); or it occurs prior to first dose date and worsens while on therapy or up to 30 days after the last dose of study treatment (or up to any time if related to study treatment). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Participants | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 52 | 49 | 48 |
SAE was defined as any untoward medical occurrence that at any dose: Resulted in death; Was life-threatening; Required inpatient hospitalization or caused prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Required intervention to prevent permanent impairment/damage; Was an important medical event (defined as a medical event that may not have been immediately life-threatening or resulted in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention to prevent one of the other serious outcomes listed in the definition above). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Participants | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 20 | 25 | 6 |
| Microgram per milliliter | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Maximum Concentration (Cmax) Ramucirumab Drug Product (DP) or Icrucumab | 308 ± 25 | — |
Minimum Concentration (Cmin) Ramucirumab Drug Product (DP) or Icrucumab.
| Micro gram per milliliter | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Cycle 2 | 23.7 ± 58 | — |
| Cycle 4 | 80.6 ± 67 | — |
| Cycle 6 | 44.7 ± 83 | — |
| Cycle 8 | 65.8 ± 43 | — |
| Cycle 10 | 66.8 ± 37 | — |
| Cycle 12 | 74.3 ± 38 | — |
| Cycle 14 | 62.5 | — |
| Cycle 16 | 50.5 | — |
| Cycle 18 | 50.5 | — |
| Cycle 22 | 55.0 | — |
Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity of Ramucirumab and Icrucumab.
| microgram*hour/mL | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Ramucirumab or Icrucumab | 54400 ± 42 | — |
Terminal half-life (t½) of Ramucirumab and Icrucumab.
| Days | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Terminal Half-life (t½) of Ramucirumab or Icrucumab | 6.80 (5.22 to 8.57) | — |
Clearance (Cl) of Ramucirumab and Icrucumab.
| Liters per hour | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Clearance (Cl) of Ramucirumab or Icrucumab | 0.0141 ± 34 | — |
Volume of Distribution at Steady State (Vss) of Ramucirumab and Icrucumab.
| Liters | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Volume of Distribution at Steady State (Vss) of Ramucirumab or Icrucumab | 3.17 ± 18 | — |
| Participants | Ramucirumab + Capecitabine | Icrucumab + Capecitabine |
|---|---|---|
| Treatment emergent antibody | 0 | — |
| Neutralizing antibody | 0 | — |
Collected over Up To 160 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab + Capecitabine | — | 20/52 (38.5%) | 51/52 (98.1%) |
| Icrucumab + Capecitabine | — | 25/49 (51%) | 49/49 (100%) |
| Capecitabine | — | 6/49 (12.2%) | 48/49 (98%) |
| Crossover to Ramucirumab DP + Capecitabine | — | 5/29 (17.2%) | 29/29 (100%) |
| Crossover to Icrucumab + Capecitabine | — | 0/1 (0%) | 1/1 (100%) |
| Event | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Crossover to Ramucirumab DP + Capecitabine | Crossover to Icrucumab + Capecitabine |
|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/52 | 8/49 | 0/49 | 0/29 | 0/1 |
| Pericardial effusionCardiac disorders | 0/52 | 4/49 | 0/49 | 0/29 | 0/1 |
| DehydrationMetabolism and nutrition disorders | 2/52 | 4/49 | 0/49 | 1/29 | 0/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/52 | 3/49 | 0/49 | 1/29 | 0/1 |
| AscitesGastrointestinal disorders | 3/52 | 0/49 | 0/49 | 0/29 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 0/52 | 2/49 | 0/49 | 0/29 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/52 | 2/49 | 1/49 | 0/29 | 0/1 |
| NauseaGastrointestinal disorders | 0/52 | 2/49 | 1/49 | 0/29 | 0/1 |
| VomitingGastrointestinal disorders | 0/52 | 2/49 | 2/49 | 1/29 | 0/1 |
| PneumoniaInfections and infestations | 0/52 | 2/49 | 1/49 | 0/29 | 0/1 |
| Event | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Crossover to Ramucirumab DP + Capecitabine | Crossover to Icrucumab + Capecitabine |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/52 | 14/49 | 12/49 | 3/29 | 1/1 |
| Vision blurredEye disorders | 2/52 | 1/49 | 0/49 | 3/29 | 1/1 |
| Abdominal pain upperGastrointestinal disorders | 3/52 | 3/49 | 3/49 | 3/29 | 1/1 |
| ChillsGeneral disorders | 4/52 | 2/49 | 2/49 | 3/29 | 1/1 |
| Face oedemaGeneral disorders | 1/52 | 9/49 | 0/49 | 0/29 | 1/1 |
| Non-cardiac chest painGeneral disorders | 1/52 | 2/49 | 1/49 | 0/29 | 1/1 |
| Oedema peripheralGeneral disorders | 13/52 | 19/49 | 6/49 | 5/29 | 1/1 |
| Neutrophil count decreasedInvestigations | 4/52 | 2/49 | 2/49 | 1/29 | 1/1 |
| Decreased appetiteMetabolism and nutrition disorders | 17/52 | 11/49 | 10/49 | 6/29 | 1/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/52 | 2/49 | 8/49 | 3/29 | 1/1 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 10.75 | 51.1 ± 11.54 | 53.5 ± 11.12 | 53.3 ± 11.19 |
| Sex: Female, Male(Participants) | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Total |
|---|---|---|---|---|
| Female | 52 | 48 | 49 | 149 |
| Male | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 1 | 6 |
| Not Hispanic or Latino | 49 | 44 | 45 | 138 |
| Unknown or Not Reported | 1 | 2 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Ramucirumab + Capecitabine | Icrucumab + Capecitabine | Capecitabine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| American Indian or Alaska Native,White | 0 | 0 | 1 | 1 |
| Asian | 2 | 1 | 1 | 4 |
| Black or African American | 13 | 8 | 4 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 36 | 37 | 39 | 112 |
| White, Other | 0 | 0 | 1 | 1 |
| Other | 1 | 2 | 2 | 5 |
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
The record gives a start of Mar 2011, a primary completion of Oct 2013 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2019, 5 years 10 months after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Icrucumab